Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HSCS HeartSciences	$3.59 -4.3%	$3.76	$2.36 ▼ $6.47	$8.54M	2.56	143,994 shs	54,031 shs
POAI Predictive Oncology	$0.90 +5.5%	$0.83	$0.55 ▼ $3.06	$9.29M	1.18	211,067 shs	238,663 shs
SINT SINTX TECHNOLOGIES	$3.29 +3.5%	$3.00	$1.71 ▼ $8.60	$8.77M	0.65	61,807 shs	148,226 shs
XAGE Longevity Health	$2.58 +5.3%	$0.00	$2.15 ▼ $38.10	$2.46M	0.51	49,711 shs	77,764 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HSCS HeartSciences	+10.95%	+0.54%	-4.34%	-16.48%	+4.75%
POAI Predictive Oncology	-0.34%	+17.59%	+8.00%	-22.44%	-2.49%
SINT SINTX TECHNOLOGIES	+4.61%	+10.42%	+14.80%	+5.30%	-28.54%
XAGE Longevity Health	-3.92%	-6.13%	-32.51%	+244,999,900.00%	+244,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HSCS HeartSciences	3.3516 of 5 stars	3.5	5.0	0.0	0.0	3.6	0.8	0.6
POAI Predictive Oncology	0.3454 of 5 stars	0.0	3.0	0.0	0.0	1.6	0.0	0.6
SINT Sintx Technologies	2.6589 of 5 stars	3.5	4.0	0.0	0.0	2.4	1.7	0.0
XAGE Longevity Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HSCS HeartSciences	3.00	Buy	$13.00	262.12% Upside
POAI Predictive Oncology	2.00	Hold	N/A	N/A
SINT SINTX TECHNOLOGIES	3.00	Buy	$28.00	751.06% Upside
XAGE Longevity Health	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest XAGE, POAI, SINT, and HSCS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/30/2025	SINT SINTX TECHNOLOGIES	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $28.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HSCS HeartSciences	N/A	N/A	N/A	N/A	$0.18 per share	N/A
POAI Predictive Oncology	$1.62M	6.05	N/A	N/A	($0.15) per share	-6.00
SINT SINTX TECHNOLOGIES	$2.89M	3.14	N/A	N/A	$1.45 per share	2.27
XAGE Longevity Health	$50K	51.60	N/A	N/A	($3.72) per share	-0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HSCS HeartSciences	-$8.77M	-$9.36	N/A	N/A	N/A	-293.60%	-135.39%	9/11/2025 (Estimated)
POAI Predictive Oncology	-$12.66M	-$3.05	N/A	N/A	-587.31%	-722.01%	-167.23%	N/A
SINT SINTX TECHNOLOGIES	-$11.02M	-$50.56	∞	N/A	-674.05%	-256.59%	-121.32%	N/A
XAGE Longevity Health	-$10.37M	N/A	∞	N/A	-682.67%	N/A	-261.90%	N/A

Latest XAGE, POAI, SINT, and HSCS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/11/2025	N/A	HSCS HeartSciences	-$2.41	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	SINT SINTX TECHNOLOGIES	-$0.79	-$0.91	-$0.12	-$0.91	$0.40 million	$0.15 million
8/14/2025	Q2 2025	XAGE Longevity Health	N/A	-$1.56	N/A	-$1.56	N/A	$0.50 million
8/13/2025	Q2 2025	POAI Predictive Oncology	-$0.09	-$0.22	-$0.13	-$0.23	$1.50 million	$0.00 million
7/24/2025	Q4 2025	HSCS HeartSciences	-$2.51	-$1.88	+$0.63	-$1.88	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HSCS HeartSciences	N/A	N/A	N/A	N/A	N/A
POAI Predictive Oncology	N/A	N/A	N/A	N/A	N/A
SINT SINTX TECHNOLOGIES	N/A	N/A	N/A	N/A	N/A
XAGE Longevity Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HSCS HeartSciences	N/A	0.59	0.41
POAI Predictive Oncology	N/A	0.32	0.31
SINT Sintx Technologies	N/A	3.44	3.25
XAGE Longevity Health	N/A	0.42	0.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HSCS HeartSciences	17.24%
POAI Predictive Oncology	9.04%
SINT SINTX TECHNOLOGIES	18.38%
XAGE Longevity Health	24.22%

Insider Ownership

Company	Insider Ownership
HSCS HeartSciences	1.80%
POAI Predictive Oncology	3.44%
SINT SINTX TECHNOLOGIES	4.08%
XAGE Longevity Health	29.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HSCS HeartSciences	10	2.28 million	2.24 million	Not Optionable
POAI Predictive Oncology	30	10.89 million	10.52 million	Not Optionable
SINT SINTX TECHNOLOGIES	40	2.76 million	2.64 million	Not Optionable
XAGE Longevity Health	14	1.00 million	713,000	N/A

XAGE, POAI, SINT, and HSCS Headlines

Recent News About These Companies

Longevity Health (NASDAQ:XAGE) versus TransEnterix (OTCMKTS:TRXDW) Financial Contrast

August 19 at 2:39 AM | americanbankingnews.com

Longevity Health (NASDAQ:XAGE) and CapsoVision (NASDAQ:CV) Financial Contrast

August 13, 2025 | americanbankingnews.com

Longevity Health (NASDAQ:XAGE) Stock Rating Upgraded by Wall Street Zen

August 9, 2025 | americanbankingnews.com

Why Longevity Health Stock Is Skyrocketing Today

July 15, 2025 | benzinga.com

Why Longevity Health Stock Is Skyrocketing Today

July 15, 2025 | benzinga.com

Why did XAGE Stock Surge in Today’s Premarket Trading?

July 15, 2025 | tokenist.comT

Longevity Health Holdings, Inc.: Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

July 15, 2025 | finanznachrichten.de

Longevity Health Holdings to Merge With True Health

July 15, 2025 | marketwatch.com

Longevity Health stock soars after merger with THPlasma in all-stock deal

July 15, 2025 | investing.com

Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

July 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XAGE, POAI, SINT, and HSCS Company Descriptions

HeartSciences NASDAQ:HSCS

$3.59 -0.16 (-4.27%)

Closing price 04:00 PM Eastern

Extended Trading

$3.62 +0.04 (+0.97%)

As of 05:51 PM Eastern

Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.

Predictive Oncology NASDAQ:POAI

$0.90 +0.05 (+5.49%)

Closing price 04:00 PM Eastern

Extended Trading

$0.90 +0.01 (+0.56%)

As of 07:50 PM Eastern

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

SINTX TECHNOLOGIES NASDAQ:SINT

$3.29 +0.11 (+3.46%)

Closing price 04:00 PM Eastern

Extended Trading

$3.26 -0.02 (-0.76%)

As of 07:17 PM Eastern

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

Longevity Health NASDAQ:XAGE

$2.58 +0.13 (+5.31%)

As of 04:00 PM Eastern

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time